Aura Biosciences Inc (AURA)

$8.03 +0.35 (4.56%)
Market Cap 797.49M
Revenue (ttm) 0.00
Net Income (ttm) -106.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 330,879
Avg Vol 661,968
Day's Range N/A - N/A
Shares Out 103.71M
Stochastic %K 58%
Beta 0.40
Analysts Strong Sell
Price Target $17.80

Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8864
Address:
80 Guest Street, 5th Floor, Boston, United States
gazza01
gazza01 Aug. 12 at 5:04 PM
$AURA seems overall positive to focus on the highest probability indication and take steps to reduce costs and have ATM availability
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 12 at 12:56 PM
$AURA (-4.2% pre) Form S-3 Aura Biosciences, Inc. https://ooc.bz/l/110987
0 · Reply
d_risk
d_risk Aug. 11 at 7:28 PM
$AURA - Aura Biosciences Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +220.8% above peer average (37,662 vs 11,741 across 655 peers). Aura now discloses completed enrollment of its pivotal Phase 3 trial but warns topline data won’t arrive until 2H 2027 and may not support approval, while a new 20% workforce reduction, leadership transition, and narrowed ocular oncology focus heighten operational and retention risks. #Biotechnology #ClinicalTrials #WorkforceReduction #LeadershipTransition #OcularOncology 🟢 Added 🟠 Removed https://d-risk.ai/AURA/10-Q/2026-08-11
1 · Reply
Doozio
Doozio Aug. 8 at 5:15 PM
It was always after da 🐑 slaughter July wen da 🧠 $AURA wud return ONTO 🐒🍌🧠⏰♾️
0 · Reply
rando321456
rando321456 Jul. 27 at 5:00 PM
$AURA This company needs to show us the goods and let us decide if it is a niche ocular cancer player or has good probability of playing in the larger indications.
1 · Reply
topstockalerts
topstockalerts Jul. 3 at 8:08 PM
$AURA the chart looks very constructive right here
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 8:20 PM
$AURA $AHMA $CULP ✨
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 7:03 PM
$AURA Added. The selling volume is minimal. I guess we'll see.
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 5:04 PM
$AURA
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 4:46 PM
$AURA
0 · Reply
Latest News on AURA
Aura Biosciences files $500M mixed securities shelf

2026-08-17T11:12:43.000Z - 1 day ago

Aura Biosciences files $500M mixed securities shelf

Aura Biosciences price target lowered to $18 from $24 at H.C. Wainwright

2026-08-11T15:30:22.000Z - 7 days ago

Aura Biosciences price target lowered to $18 from $24 at H.C. Wainwright

Aura Biosciences Registration statement: Registration filing

Aug 11, 2026, 8:00 AM EDT - 7 days ago

Aura Biosciences Registration statement: Registration filing

Aura Biosciences Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 7 days ago

Aura Biosciences Earnings release: Q2 2026

Aura Biosciences Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 7 days ago

Aura Biosciences Quarterly report: Q2 2026

Aura Biosciences Slides: Corporate presentation

Aug 10, 2026, 7:00 AM EDT - 8 days ago

Aura Biosciences Slides: Corporate presentation

Aura Biosciences Transcript: EGM 2026

Aug 5, 2026, 9:30 AM EDT - 13 days ago

Aura Biosciences Transcript: EGM 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Jul 8, 2026, 7:01 AM EDT - 5 weeks ago

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Aura Biosciences Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 7 weeks ago

Aura Biosciences Proxy statement: Proxy filing

Aura Biosciences Proxy statement: Proxy filing

Jun 17, 2026, 8:00 AM EDT - 2 months ago

Aura Biosciences Proxy statement: Proxy filing

Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario

Aura Biosciences Transcript: AGM 2026

Jun 11, 2026, 9:30 AM EDT - 2 months ago

Aura Biosciences Transcript: AGM 2026

Aura Biosciences completes enrollment in belzupacap sarotalocan trial

2026-06-01T12:46:57.000Z - 2 months ago

Aura Biosciences completes enrollment in belzupacap sarotalocan trial

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 27, 2026, 1:30 PM EDT - 2 months ago

Aura Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 19, 2026, 4:50 PM EDT - 3 months ago

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 12:00 PM EDT - 3 months ago

Aura Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Aura Biosciences price target lowered to $17 from $26 at Leerink

2026-05-12T20:33:39.000Z - 3 months ago

Aura Biosciences price target lowered to $17 from $26 at Leerink

Aura Biosciences to Participate in Upcoming Investor Conferences

May 12, 2026, 4:01 PM EDT - 3 months ago

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

May 11, 2026, 4:01 PM EDT - 3 months ago

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Aura Biosciences Earnings release: Q1 2026

Aura Biosciences Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Aura Biosciences Quarterly report: Q1 2026

Aura Biosciences Slides: Corporate presentation

May 11, 2026, 4:00 PM EDT - 3 months ago

Aura Biosciences Slides: Corporate presentation

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

May 5, 2026, 5:15 PM EDT - 3 months ago

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Aura Biosciences Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

Aura Biosciences Slides: Corporate presentation

Aura Biosciences $260M Spot Secondary priced at $6.00

2026-05-04T13:38:00.000Z - 3 months ago

Aura Biosciences $260M Spot Secondary priced at $6.00

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

May 4, 2026, 9:03 AM EDT - 3 months ago

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 3 months ago

Aura Biosciences Proxy statement: Proxy filing

Aura Biosciences announces common stock, pre-funded warrant offering

2026-05-04T10:12:08.000Z - 3 months ago

Aura Biosciences announces common stock, pre-funded warrant offering

Aura Biosciences says Natalie Holles to succeed Elisabet de los Pinos as CEO

2026-05-04T10:05:07.000Z - 3 months ago

Aura Biosciences says Natalie Holles to succeed Elisabet de los Pinos as CEO

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 4, 2026, 6:03 AM EDT - 3 months ago

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

May 4, 2026, 6:01 AM EDT - 3 months ago

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Aura Biosciences Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Aura Biosciences Proxy statement: Proxy filing

Aura Biosciences Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Aura Biosciences Proxy statement: Proxy filing

Aura Biosciences price target raised to $15 from $13 at Evercore ISI

2026-04-13T13:47:29.000Z - 4 months ago

Aura Biosciences price target raised to $15 from $13 at Evercore ISI

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Aura Biosciences Annual report: Q4 2025

Aura Biosciences Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Aura Biosciences Earnings release: Q4 2025

Aura Biosciences Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Aura Biosciences Slides: Corporate presentation

Aura Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:40 PM EDT - 5 months ago

Aura Biosciences Transcript: Leerink Global Healthcare Conference 2026

Aura Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:10 AM EST - 5 months ago

Aura Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Aura Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:50 AM EST - 9 months ago

Aura Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Aura Biosciences re-initiated with an Outperform at Evercore ISI

2025-11-25T21:40:32.000Z - 9 months ago

Aura Biosciences re-initiated with an Outperform at Evercore ISI

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 9 months ago

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Aura Biosciences reports Q3 EPS (40c), consensus (47c)

2025-11-13T12:10:46.000Z - 9 months ago

Aura Biosciences reports Q3 EPS (40c), consensus (47c)

Aura Biosciences announces cash to fund operations into 1H of 2027

2025-11-13T12:10:32.000Z - 9 months ago

Aura Biosciences announces cash to fund operations into 1H of 2027

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 13, 2025, 7:00 AM EST - 9 months ago

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Aura Biosciences Earnings release: Q3 2025

Aura Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Aura Biosciences Quarterly report: Q3 2025

Aura Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 11:00 AM EDT - 1 year ago

Aura Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

2025-08-13T11:10:59.000Z - 1 year ago

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Quarterly report: Q2 2025

Aura Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Earnings release: Q2 2025

Aura Biosciences assumed with a Buy at H.C. Wainwright

2025-05-28T10:10:24.000Z - 1 year ago

Aura Biosciences assumed with a Buy at H.C. Wainwright

Aura Biosciences Transcript: 6th Annual Oncology Innovation Summit

May 27, 2025, 10:00 AM EDT - 1 year ago

Aura Biosciences Transcript: 6th Annual Oncology Innovation Summit

Aura Biosciences Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 2:00 PM EDT - 1 year ago

Aura Biosciences Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Aura Biosciences Slides: Corporate Presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Slides: Corporate Presentation

Aura Biosciences 11.7M share Spot Secondary priced at $4.90

2025-05-15T13:35:36.000Z - 1 year ago

Aura Biosciences 11.7M share Spot Secondary priced at $4.90

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

May 15, 2025, 9:32 AM EDT - 1 year ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Aura Biosciences announces common stock, warrant offering, no amount given

2025-05-15T10:15:45.000Z - 1 year ago

Aura Biosciences announces common stock, warrant offering, no amount given

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 6:10 AM EDT - 1 year ago

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 6:01 AM EDT - 1 year ago

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Quarterly report: Q1 2025

May 15, 2025, 6:00 AM EDT - 1 year ago

Aura Biosciences Quarterly report: Q1 2025

Aura Biosciences Earnings release: Q1 2025

May 15, 2025, 6:00 AM EDT - 1 year ago

Aura Biosciences Earnings release: Q1 2025

Aura Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 9:30 AM EDT - 1 year ago

Aura Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

Aura Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences appoints Bitetti to board of directors

2025-04-02T11:15:32.000Z - 1 year ago

Aura Biosciences appoints Bitetti to board of directors

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress

2025-03-26T13:38:48.000Z - 1 year ago

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP

2025-03-26T09:40:17.000Z - 1 year ago

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP

Aura Biosciences Transcript: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Transcript: Status Update

Aura Biosciences Press release: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Press release: Status Update

Aura Biosciences Slides: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Slides: Status Update

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Aura Biosciences Annual report: Q4 2024

Mar 24, 2025, 10:30 AM EDT - 1 year ago

Aura Biosciences Annual report: Q4 2024

Aura Biosciences Earnings release: Q4 2024

Mar 24, 2025, 10:30 AM EDT - 1 year ago

Aura Biosciences Earnings release: Q4 2024

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Aura Biosciences Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Aura Biosciences Transcript: Leerink Global Healthcare Conference 2025

Aura Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

Aura Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Mar 3, 2025, 7:00 AM EST - 1 year ago

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Aura Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 2:35 PM EST - 1 year ago

Aura Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Dec 2, 2024, 4:31 AM EST - 1 year ago

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Aura Biosciences Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Aura Biosciences Earnings release: Q3 2024

Aura Biosciences Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Aura Biosciences Quarterly report: Q3 2024

Aura Biosciences Transcript: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Transcript: Status Update

Aura Biosciences Press release: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Press release: Status Update

Aura Biosciences Slides: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Slides: Status Update

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Aura Biosciences Transcript: Status Update

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Transcript: Status Update

Aura Biosciences Press release: Status Update

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Press release: Status Update

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sep 12, 2024, 6:30 AM EDT - 2 years ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Aura Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aug 26, 2024, 4:05 PM EDT - 2 years ago

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aura Biosciences Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Aura Biosciences Quarterly report: Q2 2024

Aura Biosciences Earnings release: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q2 2024

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

Aura Biosciences Proxy statement: Proxy Filing

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 12:30 PM EDT - 2 years ago

Aura Biosciences Transcript: Jefferies 2024 Global Healthcare Conference

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 4:05 PM EDT - 2 years ago

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

Aura Biosciences Transcript: Status Update

May 29, 2024, 2:00 PM EDT - 2 years ago

Aura Biosciences Transcript: Status Update

Aura Biosciences Transcript: TD Cowen 5th Annual Oncology Innovation Summit

May 29, 2024, 10:00 AM EDT - 2 years ago

Aura Biosciences Transcript: TD Cowen 5th Annual Oncology Innovation Summit

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 23, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

Aura Biosciences Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 9:00 AM EDT - 2 years ago

Aura Biosciences Transcript: The Citizens JMP Life Sciences Conference

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Aura Biosciences Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Quarterly report: Q1 2024

Aura Biosciences Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q1 2024

Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Registration statement: Registration Filing

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Registration statement: Registration Filing

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Aura Biosciences Earnings release: Q4 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q4 2023

Aura Biosciences Annual report: Q4 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Annual report: Q4 2023

Aura Biosciences Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 3:40 PM EDT - 2 years ago

Aura Biosciences Transcript: Leerink Partners Global Biopharma Conference 2024

Aura Biosciences Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 1:30 PM EST - 2 years ago

Aura Biosciences Transcript: TD Cowen 44th Annual Health Care Conference 2024

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Dec 7, 2023, 8:00 AM EST - 2 years ago

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Aura Biosciences Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 29, 2023, 4:15 PM EST - 2 years ago

Aura Biosciences Transcript: 6th Annual Evercore ISI HealthCONx Conference

Aura Biosciences Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 15, 2023, 9:30 AM EST - 2 years ago

Aura Biosciences Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Nov 9, 2023, 4:05 PM EST - 3 years ago

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Quarterly report: Q3 2023

Aura Biosciences Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Earnings release: Q3 2023

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 10:02 PM EST - 3 years ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Aura Biosciences Announces Proposed Public Offering of Common Stock

Nov 6, 2023, 4:08 PM EST - 3 years ago

Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Nov 6, 2023, 3:00 PM EST - 3 years ago

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Aura Biosciences Slides: Corporate Presentation

Nov 3, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Slides: Corporate Presentation

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Oct 31, 2023, 4:05 PM EDT - 3 years ago

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Oct 2, 2023, 4:05 PM EDT - 3 years ago

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Quarterly report: Q2 2023

Aura Biosciences Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q2 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 12, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 11, 2023, 4:10 PM EDT - 3 years ago

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Quarterly report: Q1 2023

Aura Biosciences Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q1 2023

Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Proxy statement: Proxy Filing

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Mar 15, 2023, 4:10 PM EDT - 3 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Annual report: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Annual report: Q4 2022

Aura Biosciences Earnings release: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q4 2022

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Feb 16, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Aura Biosciences Slides: Corporate Presentation

Jan 6, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Slides: Corporate Presentation

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 10, 2022, 7:00 AM EST - 4 years ago

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Nov 10, 2022, 6:45 AM EST - 4 years ago

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Registration statement: Registration Filing

Nov 1, 2022, 8:00 AM EDT - 4 years ago

Aura Biosciences Registration statement: Registration Filing

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Oct 3, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Sep 28, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Sep 27, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Sep 7, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

gazza01
gazza01 Aug. 12 at 5:04 PM
$AURA seems overall positive to focus on the highest probability indication and take steps to reduce costs and have ATM availability
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 12 at 12:56 PM
$AURA (-4.2% pre) Form S-3 Aura Biosciences, Inc. https://ooc.bz/l/110987
0 · Reply
d_risk
d_risk Aug. 11 at 7:28 PM
$AURA - Aura Biosciences Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +220.8% above peer average (37,662 vs 11,741 across 655 peers). Aura now discloses completed enrollment of its pivotal Phase 3 trial but warns topline data won’t arrive until 2H 2027 and may not support approval, while a new 20% workforce reduction, leadership transition, and narrowed ocular oncology focus heighten operational and retention risks. #Biotechnology #ClinicalTrials #WorkforceReduction #LeadershipTransition #OcularOncology 🟢 Added 🟠 Removed https://d-risk.ai/AURA/10-Q/2026-08-11
1 · Reply
Doozio
Doozio Aug. 8 at 5:15 PM
It was always after da 🐑 slaughter July wen da 🧠 $AURA wud return ONTO 🐒🍌🧠⏰♾️
0 · Reply
rando321456
rando321456 Jul. 27 at 5:00 PM
$AURA This company needs to show us the goods and let us decide if it is a niche ocular cancer player or has good probability of playing in the larger indications.
1 · Reply
topstockalerts
topstockalerts Jul. 3 at 8:08 PM
$AURA the chart looks very constructive right here
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 8:20 PM
$AURA $AHMA $CULP ✨
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 7:03 PM
$AURA Added. The selling volume is minimal. I guess we'll see.
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 5:04 PM
$AURA
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 4:46 PM
$AURA
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 4:42 PM
$AURA Took a starter. GLTA
0 · Reply
Dcvfin
Dcvfin Jun. 10 at 1:23 AM
$AURA starting to look yummy
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:59 PM
$AURA 08:14 on Jun. 01 2026 Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027 #tradeideas
0 · Reply
MarketBeat
MarketBeat May. 27 at 8:06 PM
https://marketbeat.com/a/8678516/ $AURA Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
0 · Reply
MarketBeat
MarketBeat May. 20 at 2:04 AM
https://marketbeat.com/a/8663626/ $AURA Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
0 · Reply
billionairehedgeclub
billionairehedgeclub May. 19 at 6:33 PM
$AURA I’m in
0 · Reply
gazza01
gazza01 May. 13 at 12:37 PM
$REPL $AURA doesn't AURA also use modified HPV virus to target melanoma? Hopefully they'll learn from REPL mistakes
3 · Reply
Dcvcool
Dcvcool May. 6 at 12:55 AM
$AURA seems like this finally came up to somewhere close to true value with this experienced CEO taking over Great trial results so far I think this will do well
1 · Reply
Uromaster
Uromaster May. 5 at 2:30 PM
$AURA I am amazed how this stock is riding under the radar. Good movement. Maybe take my winnings and run?
1 · Reply
StockScanners
StockScanners May. 5 at 5:28 AM
$AURA keep watch if this holds above 8
0 · Reply
topstockalerts
topstockalerts May. 4 at 10:47 PM
$AURA this could easily turn into one of those annoying runners you miss 😅
0 · Reply
rando321456
rando321456 May. 4 at 3:19 PM
$AURA That's nearly a ggs here assuming the results of Compass tracks to what the phase 2 showed. We now have both the capital and the enrollment to drive this past the finish line. What's very interesting is that they probably raised about 50-100 million more than they needed to, that tells me they are going to be aggressive with their pipeline and maybe self fund another phase 3. We shall see.
0 · Reply